健脾清肝合剂防治肝癌TACE后肝功能损害的临床研究

Clinical Study on "Jianpi Qinggan Mixture" in Treating and Preventing Liver Functional Lesion Following TACE for Liver Cancer

目的探讨健脾清肝合剂对肝癌肝动脉栓塞化疗(TACE)后肝功能损害的防治作用。方法将86例患者随机分为治疗组和对照组各43例,治疗组在行TACE治疗前1周开始服用健脾清肝合剂,对照组在TACE治疗后出现肝功能损害时加用凯西莱口服;服药2个月后比较治疗前后肝功能变化及治疗后组间各项肝功能指标的差异。结果对照组第1次介入后第3d血清AST、ALT均升高,与治疗前比较,差异有统计学意义(P<0.05);对照组第1次介入后第14d血清ALB降低,与治疗前比较,差异有统计学意义(P<0.05);治疗组与对照组第2次介入后第28d的AST值比较差异有统计学意义(P<0.05)。结论肝癌患者在行肝动脉化疗栓塞治疗时,配合服用健脾清肝合剂可在一定程度上防治TACE治疗所致的肝功能损害。

Objective To evaluate the effect of ＂Jianpi Qinggan Mixture＂ in preventing and treating liver functional lesion following transeatheter arterial ehemo-embolization（TACE） for liver cancer. Method Eighty-six subjects were randomly divided into two groups： treatment group in which 43 eases began to take ＂Jianpi Qinggan Mixture＂ one week before TACE and control group in which 43 eases took orally Tiopronin when liver function was impaired after TACE. The liver function were observed. Results The levels of AST and ALT in control group were increased on the 3rd day after the first TACE （P〈0.05）, and were decreased on the 14th day after the first TACE （P〈0.05）. There was a significant difference of AST in blood serum on the 28th day between the two groups （P〈0.05）. Conchlsion For patients with primary hepatic carcinoma（PHC）, ＂Jianpi Qinggan Mixture＂ can help TACE in the treatment and prevention of liver cancer.